Shooting STAR: reinterpreting the data from the 'Single Embryo TrAnsfeR of Euploid Embryo' randomized clinical trial

REPRODUCTIVE BIOMEDICINE ONLINE

卷:40

Editorial Material

Pagliardini, Luca¹  Vigano, Paola¹  Alteri, Alessandra²  Corti, Laura²  Somigliana, Edgardo^3,4  Papaleo, Enrico² 

[1] IRCCS San Raffaele Sci Inst, Div Genet & Cell Biol, Reprod Sci Lab, I-20132 Milan, Italy

[2] IRCCS San Raffaele Sci Inst, Obstet & Gynecol Unit, I-20132 Milan, Italy

[3] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Obstet & Gynaecol Dept, Via M Fanti 6, I-20122 Milan, Italy

[4] Univ Milan, Dipartimento Sci Clin & Comunita, Via Fanti 6, I-20122 Milan, Italy

关键词: Biopsy;    Euploid;    PGT-A;    STAR trial;   

DOI  :  10.1016/j.rbmo.2020.01.015

来源: Elsevier

【 摘 要 】

Preimplantation genetic testing for aneuploidy (PGT-A) still remains controversial in clinical practice. Recently, the randomized controlled trial, 'Single Embryo TrAnsfeR of Euploid Embryo' (STAR) by Munne and coworkers showed a similar live birth rate per intention to treat in the two study groups (PGT-A and controls). A wrong diagnosis and/or biopsy-related damage to the embryo might underlie these results. To assess the impact of these factors on the efficiency of PGT-A, the live birth rate of 'euploid' embryos transferred in the PGT-A group was compared with its ideal value, namely the live birth rate of embryos with the potential to implant and to give rise to a baby in the control group. This estimate has been derived using the results of the genetic testing reported in the STAR trial. According to this model, the STAR trial has demonstrated that transferring only blastocysts classified as 'euploid' after PGT-A leads to a reduction from 82.2% to 50.0% of the live birth rate for competent embryos, thus supporting the idea that PGT-A is associated with some embryo wastage.

【 授权许可】

Free